Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
Pediatric Pulmonology2024Vol. 59(10), pp. 2606–2613
Citations Over TimeTop 10% of 2024 papers
Abstract
This is the first prospective longitudinal study of mental health and sleep changes after ETI commencement in adolescents with CF. Although respiratory outcomes improved, ETI did not improve anxiety, depression or sleep.
Related Papers
- → WS6.3 Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation(2012)4 cited
- → 199 Effect of ivacaftor (Kalydeco™) on the pancreatic function of a child with cystic fibrosis (CF)(2016)1 cited
- → WS17.06 Impact of elexacaftor/tezacaftor/ivacaftor on lung-recruited neutrophils in cystic fibrosis(2022)
- → P040 Sweat chloride values in cystic fibrosis patients after one year on elexacaftor/tezacaftor/ivacaftor(2023)
- → P053 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis with responsive CFTR variants without previous modulators therapy(2024)